Jane Street’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jane Street’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$719K	Buy	19,800 +12,600	+175%	+$563K	﹤0.01%	7220
2025 Q4	$335K	Sell	7,200 -13,600	-65%	-$605K	﹤0.01%	8586
2025 Q3	$866K	Buy	+20,800	New	+$665K	﹤0.01%	6630
2024 Q2	–	Sell	-7,000	Closed	-$328K	–	9469
2024 Q1	$328K	Sell	7,000 -4,100	-37%	-$160K	﹤0.01%	7417
2023 Q4	$395K	Sell	11,100 -51,500	-82%	-$1.58M	﹤0.01%	7176
2023 Q3	$1.86M	Buy	+62,600	New	+$1.29M	﹤0.01%	4171

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jane Street's CRNX Position: Q4 2025 in Review

Jane Street sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 13,982 shares — an estimated $622K sold.

Jane Street first reported a position in CRNX in Q2 2020 and held it in 11 quarters. The position peaked at $6.62M in Q3 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

Jane Street reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Jane Street sold 13,982 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $622K.
Jane Street first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 11 quarters.
Jane Street's Crinetics Pharmaceuticals position peaked at $6.62M in Q3 2024.
240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.